A Phase II Study With A Safety Lead-In Of Nivolumab In Combination With Bevacizumab For The Treatment Of Relapsed Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 24 Jul 2018
At a glance
- Drugs Nivolumab (Primary) ; Bevacizumab
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 17 Jul 2018 Status changed from recruiting to active, no longer recruiting.
- 10 Jun 2017 Biomarkers information updated
- 27 Feb 2017 Status changed from not yet recruiting to recruiting.